Suleymanova N. M., Shamkhalova I. A.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

The aim of the study was to assess the serum adiponectin concentration in pregnant women with polycystic ovary syndrome (PCOS) and body weight disorders. Methods. A total of 92 pregnant women in the period of pregnancy 8-14 weeks were examined. Of the examined, 72 pregnant women with PCOS were the main group, whose age ranged from 20 to 35 years and averaged 29.1±1.74 years. A control group included 20 pregnant women without PCOS, with an average age of 27.9±0.88 years. Body mass index (BMI) was used to estimate the degree of overweight or obesity, which was calculated using the formula G. Brey (1978). Insulin resistance indices: HOMA-IR (Homeostasis model assessment of Insulin Resistance) were calculated by the formula. QUICKI (Quantitative insulin sensitivity check index) was determined by the formula: l/ log(fasting glucose level) + log(fasting insulin level). The level of adiponectin in blood serum was determined by enzyme immunoassay (ELISA) using the test kit Mediagnost E09 Adiponectin-ELISA (Germany), according to the attached instructions on the immune analyzer Cobas Integra (Germany). Results. In the main group, compared with the control group, women aged 20 to 25 years were 55.6% (p<0.05) less frequent. On the contrary, in the older age group – 31-35 years of patients of the main group compared with the control group were significantly more frequent (by 57.3%, p<0.01). Patients with PCOS (main group) from infectious diseases, suffered in childhood, the most frequently observed measles – 19.4% (control – 5.0%, p<0.01). According to anamnesis data, 38 (52.8%) women in the main group and 5 (25.0%) women in the control group reported respiratory viral infectious diseases (SARS), with women with PCOS sick with SARS 2 and 3 times a year. In women with PCOS, the onset of menstruation was timely. The mean age of menarche onset was 13.3±0.3 years in the study group and 13.0±0.4 years in the control group. However, later there was a change in the cycle and formed a number of violations, which most often manifested oligoamenorrhea (80.6%, control – 0) in the form of menstrual delays, dysmenorrhea (34.7%, control – 5.0%). Patients with PCOS had a history of pregnancies induced by various methods, which ended with termination of pregnancy. Thus, spontaneous miscarriage was observed in 16.7% of cases, ectopic and non-developing pregnancy in 9.7 and 6.9% of cases, respectively. In patients of the main group, the most common disorder was fat metabolism, which was manifested by overweight and obesity, and the abdominal type of obesity was noted. In the main group, the number of women with impaired fat metabolism was significantly higher than the control group by 13.9 times (p<0.001). The following diseases in the frequency of occurrence were diseases of the cardiovascular system (CCC), which manifested arterial hypertension and neurocirculatory dystonia and were found in 30 (41.7%) pregnant women with PCOS. At the same time, they were not observed in pregnant women of the control group. Disorders of carbohydrate metabolism were manifested by hyperinsulinemia and high blood sugar in 12 patients. According to the data obtained, excessive hair loss occurred in 56 (77.8%) patients of the main group. The hirsute force number on the Ferriman-Hollway scale averaged 27.60±0.77.In 50 (69.4%) patients of the main group with impaired fat metabolism, BMI was on average 30.2±0.65 kg/m2. Conclusion. The lowest adiponectin concentration in the blood was observed in patients with elevated BMI, which confirms the fact that the adiponectin concentration in the blood decreases depending on the BMI.

pregnancy, PCOS, metabolic disorders, BMI, adiponectin

1. Dubrovina SO. Sindrom polikistoznyh jaichnikov: strategija obsledovanija i lechenija. Problemy reprodukcii. 2014;6:10-6. [in Russiаn].
2. Podzolkova NM, Koloda JuA. Sovremennye predstavlenija o sindrome polikistoznyh jaichnikov. Farmateka. 2016;3:8-15. [in Russiаn].
3. SPKJa: ot peresmotra predstavlenij k novym terapevticheskim strategijam. Sovremennye nauchnye dannye i klinicheskie rekomendacii MZ RF 2015 goda. Informacionnyj bjulleten’. Pod red. EN. Andreevoj, MB. Hamoshinoj. M.: Redakcija zhurnala StatusPraesens. 2016. р. 28. [in Russiаn].
4. Araki T, Elias R, Rosenwaks Z, Poretsky L. Achieving a Successful Pregnancy in Women with Polycystic Ovary Syndrome. Endocrinol Metab Clin N Am. 2011;40:865-94.
5. Hai-Feng Yu, Hong-Su Chen, Da-Pang Rao, Jian Gong. Association between polycystic ovary syndrome and the risk of pregnancy complications. A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2016;95(51):e4863. DOI: 10.1097/MD.0000000000004863
6. Alieva JeA, Ovsjannikova TV, Pshenichnikova TJa. Besplodie, obuslovlennoe sindromom polikistoznyh jaichnikov. Akush. i gin. 1991;6:59-62. [in Russiаn].
7. Alieva JeA, Fanchenko ND, Parshutin NP. Jeffekt snizhenija massy tela u bol’nyh s sindromom polikistoznyh jaichnikov. Akush. i gin. 1993;3:336. [in Russiаn].
8. Guriev TD. Sindrom polikistoznyh jaichnikov. Akusherstvo, ginekologija i reprodukcija. 2010;2:10-5. [in Russiаn].
9. Shestakova IG, Rjabinkina TS. SPKJa: novyj vzgljad na problemu. Mnogoobrazie simptomov, differencial’naja diagnostika i lechenie SPKJa. Informacionnyj bjulleten’. Pod red. VE. Radzinskogo. Moskva: Redakcija zhurnala StatusPraesens; 2015. 24 s. [in Russiаn].
10. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41.
11. Dedov II, Butrova SA. Sindrom polikistoznyh jaichnikov i metabolicheskij sindrom. Ozhirenie i metabolizm. 2006;1:30-40. [in Russiаn].
12. Panarina OV, Rashidova MA, Belen’kaja LV, Trofimova TA, Sholohov LF. Sovremennye predstavlenija o patogeneze sindroma polikistoznyh jaichnikov (obzor literatury). Acta Biomedica Scientifica. 2017;2(4):9-14. [in Russiаn].
13. Escobar-Morreale HF. Adiponectin and resistin in PCOS: A clinical, biochemical and molecular genetic study. Human reproduction. 2006;21:2257-65.
14. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ. J. 2004;68:975-81.
15. Sara Jafari, Mitra Niafar, Sajjad Hejazi. The Level of Adiponectin in Polycystic Ovary Syndrome Patients Suffering Metabolic Syndrome. Life Sci J. 2013;10(7s):573-7.
16. Mirza SS, Shafique K, Shaikh AR, Khan NA, Qureshi MA. Association between circulating adiponectin levels and polycystic ovarian syndrome. Journal of Ovarian Research. 2014;7:18.
17. World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2191-4.
18. Shatha H Ali, Abdul-aziz Ali R, Bushra J. Al-Mosawy. Adiponectin to leptin ratio as a marker of insulin resistance in women with polycystic ovary syndrome (PCOS) in relation to BMI. International Journal of Research and Development in Pharmacy and Life Sciences. 2016 Dec-Jan; 5(1):1921-8. Available from: http//www.ijrdpl.com 

«Bulletin of problems biology and medicine» Issue 2 (144), 2018 year, 232-236 pages, index UDK 616.155.194.8-055.26

10.29254/2077-4214-2018-2-144-232-236